



899 NORTH CAPITOL ST. NE – 2ND FLR. WASHINGTON, DC 20002

February 6, 2020

9:30am

OPEN SESSION AGENDA

Board of Pharmacy Mission Statement:

"To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians."

PRESIDING: BOARD MEMBERSHIP/ATTENDANCE:			
	DR .TAMARA MCCANTS, PHARM.D. R.PH CHAIRPERSON		
	Dr. Benjamin Miles, Pharm.D. R.PH		
	Mr. Alan Friedman, R.PH		
	DR. ASHLEE BOW, PHARM.D. R.PH		
	CHIKITA SANDERS, CONSUMER BOARD MEMBER		
	GREGORY CENDANA, CONSUMER MEMBER		
STAFF:	SHAUNA WHITE, EXECUTIVE DIRECTOR		
	KARIN BARRON, HEALTH LICENSING SPECIALIST		
	LUANNE GREENAWAY, HEALTH LICENSING SPECIALIST		
	COUNTEE GILLIAM, BOARD INVESTIGATOR		
LEGAL STAFF:	CARLA WILLIAMS, ASSISTANT GENERAL COUNSEL		
220/1201/111			
VISITORS:			
VISITORS:			

CALL TO ORDER:

Open Session Agenda

Quorum:

Introduction:		
0206-O-01	Approval of the Open Session Meeting Minutes	
	(a) December 5, 2019	
Consent Agenda	None	
Executive Director Report	Licensing Report Statistics Prescription Monitoring Program Update Opioid Strategic Plan DC Board of Pharmacy CE Audit Update NARCAN Pilot-Free NARCAN at Select DC Pharmacies Pharmaceutical Detailer Renewal NABP Delegate Meeting	
Assistant General Counsel Report	None	Ms. Carla Williams
Subcommittee Reports		
0206-0-02	Legislative and Regulatory Subcommittee Report	Mr. Alan Friedman
0206-O-03	Communications Subcommittee Report	Dr. Ashley Bow
0206-0-04	Student Presentation-Summary of NABP News	
NABP E- Newsletter	January 15, 2020 NABP Seeks Committee and Task Force Volunteers Former Doctor Pleads Guilty in Conspiracy to Unlawfully Sell Prescription Drugs Through Rogue Internet Pharmacy Organization Mylan Recalls Three Lots of Nitzatidine Capsules Due to NDMA Impurities January 28 FDA Drug Topics Webinar to Address Funding Opportunities to Reduce Preventable Harm	Dr. Tamara McCants

	Incompanies Incompanies
	<u>January 09, 2020</u>
	NASEM Report Recommends Framework for Opioid Prescribing Guidelines for Acute Pain
	Policy Perspectives: Impact of CBD-Derived Products on State Boards of Pharmacy
	Aurobindo Pharma Issues Mirtazapine Recall Due to Dosage Label Error
	Pharmacists Continue to Be Seen as Trustworthy, According to Latest Gallup Poll Results
	Reminder: Social Media Kit Available to Help Pharmacists Educate Consumers About Drug Safety
	Note to the Public: To receive weekly updates from NABP, please sign up by using the following link: https://nabp.pharmacy/newsroom/news/
Public Comments	
Motion to Adjourn the Open Session	"Madam Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14)." (Roll Call Vote)

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at __:__

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.